RecruitingPhase 2NCT06961955
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
FAST NOVEMBER: A Phase II Randomized Trial of a 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
Sponsor
University of Utah
Enrollment
144 participants
Start Date
May 21, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.
Eligibility
Sex: FEMALEMin Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is comparing two schedules of radiation therapy after lumpectomy (breast-conserving surgery): a 5-day course versus a 9-day course — both of which are much shorter than the traditional multi-week approach. Researchers want to find out if a 5-day schedule works just as well for women with breast cancer who have certain higher-risk features.
**You may be eligible if...**
- You are a woman aged 18 or older
- You have been diagnosed with invasive breast cancer or DCIS (early-stage non-invasive breast cancer)
- Your cancer is stage T0–T3, N0, M0 (early-stage, no lymph node spread, no distant spread)
- You had a lumpectomy within the past 84 days with clear surgical margins
- You have at least one higher-risk feature (e.g., grade 3 cancer, low hormone receptor levels, lymphovascular invasion, close margins, or you are 50 or younger)
**You may NOT be eligible if...**
- You have cancer in both breasts
- You had prior radiation to the chest
- You had prior chemotherapy
- Your cancer has spread to lymph nodes or other organs
- You had a prior breast cancer in either breast
- You have severe heart disease or a recent stroke or blood clot
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RADIATIONRadiation Therapy
Undergo hypofractionated radiation therapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06961955
Related Trials
Utility of a Mobile Application for Young Women With Breast Cancer
NCT070090931 location
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT0710010645 locations
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT028307241 location
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767150 locations
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT0740580145 locations